Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects

Sulbactam-durlobactam is being developed for the treatment of infections caused by Acinetobacter baumannii, including those caused by multidrug- and carbapenem-resistant isolates. This was a phase 1 study to evaluate the effects of various degrees of renal impairment, including subjects with end-sta...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrob Agents Chemother
Main Authors: O’Donnell, John, Preston, Richard A., Mamikonyan, Grigor, Stone, Emily, Isaacs, Robin
Format: Artigo
Language:Inglês
Published: American Society for Microbiology 2019
Subjects:
Clinical Therapeutics
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6709459/
https://ncbi.nlm.nih.gov/pubmed/31307978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00794-19
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items